From Strategy and Development to Infusion and Safety Follow-up
For decades, UBC has served as a trusted partner in bringing first-in-class, new molecular entities to market. We understand the challenges that our biopharmaceutical partners are facing when considering their clinical development, post-approval, and commercial evidence generation strategies.
We are a multidisciplinary, epidemiology-backed team of peri- and post-approval research experts, safety and risk management experts, and patient access experts who harness strong experience across the development lifecycle for cellular and gene therapies. We are passionate caregivers and educators that support and guide our clients and their patients toward accessing these life-changing therapies.
Relapsed or refractory large B-cell lymphoma • Relapsed/refractory mantle cell lymphoma (r/r MCL) • B-cell precursor acute lymphoblastic leukemia (ALL)
Spinal Muscular Atrophy • Hemophilia A • Hemophilia B • BCG-unresponsive high-grade non-muscle invasive bladder cancer (NMIBC)